Premium
The use of omalizumab for treatment‐refractory chronic spontaneous urticaria in a West Australian outpatient cohort
Author(s) -
Farrah Georgia,
Stevenson Brittany,
Lie Katie,
Brusch Anna
Publication year - 2019
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.14245
Subject(s) - omalizumab , medicine , refractory (planetary science) , cohort , chronic urticaria , retrospective cohort study , pediatrics , immunoglobulin e , immunology , antibody , physics , astrobiology
There is a lack of real‐world data on the use of omalizumab in treatment‐refractory chronic spontaneous urticaria (CSU). A single‐centre retrospective cohort study was performed to assess the efficacy and safety of omalizumab for treatment‐refractory CSU. The overall response rate of 67% is comparable with that reported in the literature. Disease control and sustained remission can be achieved with omalizumab, even in patients with treatment‐resistant CSU.